Clinical Trial

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Study Description

Lipoic Acid for Progressive Multiple Sclerosis (MS)

The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Lipoic acid

1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.

Drug - Placebo

The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation

Additional Information

Official Study Title

Lipoic Acid for the Treatment of Progressive Multiple Sclerosis

Clinical Trial ID

NCT03161028

ParticipAid ID

YerGEa